Adaptive Biotechnologies (ADPT) Restructuring Costs (2024 - 2026)

Adaptive Biotechnologies (ADPT) posted Restructuring Costs of $643000.0 for Q1 2026, up 639.08% sequentially from $87000.0 in Q4 2024.

Adaptive Biotechnologies (ADPT) Restructuring Costs (2024 - 2026) Analysis & Trends

Adaptive Biotechnologies has reported Restructuring Costs for 2 years, with the latest figure at $643000.0 in Q1 2026.

Quarterly Restructuring Costs changed N/A year-over-year to $643000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $923000.0 (down 3.85% YoY) and the FY2024 annual result came in at $2.0 million, changed N/A from the prior year.
Restructuring Costs rose to $643000.0 in Q1 2026 per ADPT's latest filing, from $87000.0 in the prior quarter.
Over five years, Restructuring Costs peaked at $1.0 million in Q1 2024 and troughed at $87000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	213.77 Bn	209.71 Bn	8.34 Bn
2	Danaher	139.78 Bn	135.43 Bn	3.61 Bn
3	Idexx Laboratories	46.04 Bn	45.85 Bn	779.09 Mn
4	Agilent Technologies	39.68 Bn	37.88 Bn	990.00 Mn
5	Iqvia Holdings	39.34 Bn	37.26 Bn	1.44 Bn
6	Natera	38.75 Bn	37.65 Bn	696.04 Mn
7	Illumina	29.90 Bn	28.73 Bn	770.00 Mn
8	Mettler Toledo International	28.58 Bn	28.53 Bn	650.22 Mn
9	Quest Diagnostics	26.18 Bn	25.55 Bn	1.03 Bn
10	Adaptive Biotechnologies	3.83 Bn	3.61 Bn	52.17 Mn

Download Data